

Frank Buttgereit

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8394532/frank-buttgereit-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

232
papers

13,880
citations

55
h-index

113
g-index

265
ext. papers

17,125
ext. citations

5.5
avg. IF

6.45
L-index

#	Paper	IF	Citations
232	MIF does only marginally enhance the pro-regenerative capacities of DFO in a mouse-osteotomy-model of compromised bone healing conditions. <i>Bone</i> , 2022 , 154, 116247	4.7	1
231	Optimization of a Tricalcium Phosphate-Based Bone Model Using Cell-Sheet Technology to Simulate Bone Disorders. <i>Processes</i> , 2022 , 10, 550	2.9	0
230	Metabolic reprogramming of synovial fibroblasts in osteoarthritis by inhibition of pathologically overexpressed pyruvate dehydrogenase kinases.. <i>Metabolic Engineering</i> , 2022 , 72, 116-132	9.7	0
229	Looking ahead: giant-cell arteritis in 10 years time. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X2210963	3.8	0
228	Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human Monocytes. <i>Frontiers in Immunology</i> , 2021 , 12, 730672	8.4	0
227	The Experiences of Functioning and Health of Patients With Primary Sjögrenß Syndrome: A Multicenter Qualitative European Study. <i>Frontiers in Medicine</i> , 2021 , 8, 770422	4.9	0
226	Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 5282-5291	3.9	0
225	A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. <i>British Journal of Sports Medicine</i> , 2021 ,	10.3	7
224	Fracture Healing Research-Shift towards In Vitro Modeling?. <i>Biomedicines</i> , 2021 , 9,	4.8	4
223	Surface AMP deaminase 2 as a novel regulator modifying extracellular adenine nucleotide metabolism. <i>FASEB Journal</i> , 2021 , 35, e21684	0.9	0
222	Reply to: What could a new disease activity score for polymyalgia rheumatica do better?. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 185-186	8.1	1
221	Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trials. <i>Age and Ageing</i> , 2021 , 50, 1988-1996	3	2
220	Response to: Correspondence on Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countriesPby Nokhatha. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e171	2.4	2
219	New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cells. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 520-522	15.4	
218	Functional Scaffold-Free Bone Equivalents Induce Osteogenic and Angiogenic Processes in a Human In Vitro Fracture Hematoma Model. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1189-1201	6.3	3
217	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>RMD Open</i> , 2021 , 7,	5.9	6
216	GCA management guidelines - vive la différence?. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 649-650	8.1	0

215	How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. <i>Joint Bone Spine</i> , 2021 , 89, 105285	2.9	0
214	Systematic review on the reporting accuracy of experimental details in publications using mouse femoral fracture models. <i>Bone</i> , 2021 , 152, 116088	4.7	2
213	Using subdomain-specific item sets affected PROMIS physical function scores differently in cardiology and rheumatology patients. <i>Journal of Clinical Epidemiology</i> , 2020 , 127, 151-160	5.7	1
212	European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. <i>United European Gastroenterology Journal</i> , 2020 , 8, 637-666	5.3	39
211	Macroscale mesenchymal condensation to study cytokine-driven cellular and matrix-related changes during cartilage degradation. <i>Biofabrication</i> , 2020 , 12, 045016	10.5	4
210	Views on glucocorticoid therapy in rheumatology: the age of convergence. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 239-246	8.1	31
209	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020 , 59, 487-494	3.9	27
208	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020 , 59, e1-e23	3.9	57
207	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	3.4	851
206	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020 , 6,	5.9	37
205	Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1400-1405	5.3	1
204	The in vitro human fracture hematoma model - a tool for preclinical drug testing. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020 , 37, 561-578	4.3	4
203	Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
202	A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	4
201	Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2020 , 35, 460-461	0.9	
200	Can we shift the benefit/risk ratio of glucocorticoids?. <i>Lancet Rheumatology, The</i> , 2020 , 2, e5-e6	14.2	3
199	P235 Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study. <i>Rheumatology</i> , 2020 , 59,	3.9	1
198	Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis. <i>Current Rheumatology Reports</i> , 2020 , 22, 85	4.9	3

197	Optimal temporal artery biopsy length for diagnosis of giant cell arteritis. <i>Lancet Rheumatology, The</i> , 2020 , 2, e730-e732	14.2	
196	Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 481-495	8.1	16
195	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 267-276	4.0	20
194	Challenges, collaboration, and innovation in rheumatology education during the COVID-19 pandemic: leveraging new ways to teach. <i>Clinical Rheumatology</i> , 2020 , 39, 3535-3541	3.9	11
193	Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 2955-2963	5.6	17
192	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 993-994	27.4	8
191	Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta-Regression Analyses. <i>Arthritis Care and Research</i> , 2020 , 72, 1490-1496	4.7	1
190	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 19-30	2.4	270
189	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	26
188	Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study. <i>Journal of Experimental Orthopaedics</i> , 2019 , 6, 19	2.3	8
187	Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. <i>RMD Open</i> , 2019 , 5, e000889	5.9	14
186	An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 581-590	4.1	19
185	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1160-1166	2.4	16
184	Hypoxia and mesenchymal stromal cells as key drivers of initial fracture healing in an equine in vitro fracture hematoma model. <i>PLoS ONE</i> , 2019 , 14, e0214276	3.7	13
183	The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend. <i>Rheumatology</i> , 2019 , 58, 580-587	3.9	7
182	Metabolism of T Lymphocytes in Health and Disease. <i>International Review of Cell and Molecular Biology</i> , 2019 , 342, 95-148	6	12
181	Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System. <i>Frontiers in Immunology</i> , 2019 , 10, 1744	8.4	79
180	Administration of Tramadol or Buprenorphine via the drinking water for post-operative analgesia in a mouse-osteotomy model. <i>Scientific Reports</i> , 2019 , 9, 10749	4.9	15

179	Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2019 , 34, 253-261	0.9	7
178	Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 549-567	2.4	5
177	OP0030 RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB 2019 ,		4
176	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019 , 5, e001003	5.9	26
175	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019 , 5, e001020	5.9	27
174	Spatial Distribution of Macrophages During Callus Formation and Maturation Reveals Close Crosstalk Between Macrophages and Newly Forming Vessels. <i>Frontiers in Immunology</i> , 2019 , 10, 2588	8.4	16
173	Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 983-989	5.3	9
172	Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application. <i>Acta Biomaterialia</i> , 2019 , 86, 171-184	10.8	18
171	Reply. <i>Arthritis Care and Research</i> , 2019 , 71, 577-578	4.7	
170	Unraveling the role of hypoxia-inducible factor (HIF)-1 α and HIF-2 α in the adaption process of human microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of macrophage migration inhibitory factor. <i>Microvascular Research</i> , 2018 , 116, 34-44	3.7	17
169	Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. <i>Nutrition</i> , 2018 , 55-56, 51-55	4.8	23
168	Role of 11 β HSD type 1 in abnormal HPA axis activity during immune-mediated arthritis. <i>Endocrine Connections</i> , 2018 , 7, 385-394	3.5	5
167	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018 , 19, 67	2.8	24
166	CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	17
165	Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. <i>Rheumatology International</i> , 2018 , 38, 569-577	3.6	25
164	Will we ever have better glucocorticoids?. <i>Clinical Immunology</i> , 2018 , 186, 64-66	9	15
163	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018 , 4, e000756	5.9	8
162	EULAR points to consider for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018 , 4, e000780	5.9	8

161	Prevention of glucocorticoid morbidity in giant cell arteritis. <i>Rheumatology</i> , 2018 , 57, ii11-ii21	3.9	21
160	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 543-546	2.4	80
159	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	7.4	1649
158	Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. <i>RMD Open</i> , 2017 , 3, e000426	5.9	12
157	Differences in biomarkers of cartilage matrix turnover and their changes over 2 years in adolescent and adult volleyball athletes. <i>Journal of Experimental Orthopaedics</i> , 2017 , 4, 7	2.3	8
156	Metabolic regulation of inflammation. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 267-279	8.1	123
155	"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017 , 69, 1134-1141	4.7	29
154	Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 187-195	5.9	25
153	Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2017 , 24, 11-20	2.5	9
152	Plant-derived pectin nanocoatings to prevent inflammatory cellular response of osteoblasts following infection. <i>International Journal of Nanomedicine</i> , 2017 , 12, 433-445	7.3	5
151	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 578-592	8.1	95
150	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017 , 44, 1515-1521	4.1	24
149	A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	29
148	Nanocoating with plant-derived pectins activates osteoblast response in vitro. <i>International Journal of Nanomedicine</i> , 2017 , 12, 239-249	7.3	12
147	The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. <i>Rheumatology</i> , 2017 , 56, 506-515	3.9	62
146	Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies. <i>Rheumatology</i> , 2016 , 55, ii3-ii5	3.9	25
145	Rheumatology Workforce Planning in Western Countries: A Systematic Literature Review. <i>Arthritis Care and Research</i> , 2016 , 68, 1874-1882	4.7	18
144	Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2442-58	27.4	227

143	Effects of PVA-coated nanoparticles on human T helper cell activity. <i>Toxicology Letters</i> , 2016 , 245, 52-8	4.4	11
142	Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 75-90, viii	2.4	24
141	Imaging: Whole-body MRI undresses polymyalgia rheumatica. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 140-1	8.1	
140	Disentangling the effects of tocilizumab on neutrophil survival and function. <i>Immunologic Research</i> , 2016 , 64, 665-76	4.3	8
139	Modification of the surface of superparamagnetic iron oxide nanoparticles to enable their safe application in humans. <i>International Journal of Nanomedicine</i> , 2016 , 11, 5883-5896	7.3	17
138	Sustained Increase of 25-Hydroxyvitamin D Levels in Healthy Young Women during Wintertime after Three Suberythemal UV Irradiations-The MUVY Pilot Study. <i>PLoS ONE</i> , 2016 , 11, e0159040	3.7	7
137	Association Between the Use of Oral Contraceptives and Patient-Reported Outcomes in an Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2016 , 68, 400-5	4.7	2
136	Rheumatoid arthritis: Glucocorticoid therapy and body composition. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 444-5	8.1	3
135	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 952-7	2.4	153
134	Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts Attenuates Joint Inflammation in Collagen Antibody-Induced Arthritis. <i>American Journal of Pathology</i> , 2016 , 186, 1293-301	5.8	8
133	Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis. <i>Journal of Periodontology</i> , 2016 , 87, 763-71	4.6	16
132	Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 848-856	2.2	8
131	Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?. <i>RMD Open</i> , 2015 , 1, e000027	5.9	33
130	Cytokine expression in human osteoblasts after antiseptic treatment: a comparative study between polyhexanide and chlorhexidine. <i>Journal of Investigative Surgery</i> , 2015 , 28, 1-7	1.2	15
129	The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. <i>Steroids</i> , 2015 , 102, 27-31	2.8	23
128	Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 349-56	8.1	63
127	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1799-807	2.4	127
126	Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters. <i>Cellular and Molecular Immunology</i> , 2015 , 12, 483-92	15.4	25

125	Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. <i>RMD Open</i> , 2015 , 1, e000134	5.9	16
124	Effects of PVA coated nanoparticles on human immune cells. <i>International Journal of Nanomedicine</i> , 2015 , 10, 3429-45	7.3	28
123	Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries. <i>Rheumatology International</i> , 2015 , 35, 1791-7	3.6	8
122	2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2569-80	9.5	58
121	Cellular energy metabolism in T-lymphocytes. <i>International Reviews of Immunology</i> , 2015 , 34, 34-49	4.6	17
120	Systemic glucocorticoids in rheumatology 2015 , 423-433		1
119	Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 34-43	2.2	16
118	Novel glucocorticoids: where are we now and where do we want to go?. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S29-33	2.2	13
117	Glucocorticoids in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S34-6	2.2	14
116	Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1318, 1-6	6.5	28
115	Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 31	2.8	6
114	Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?. <i>Journal of Leukocyte Biology</i> , 2014 , 95, 233-41	6.5	45
113	NADPH oxidase 4 represents a potential target for the treatment of osteoporosis. <i>Cellular and Molecular Immunology</i> , 2014 , 11, 317-9	15.4	3
112	Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis. <i>Rheumatology International</i> , 2014 , 34, 1751-8	3.6	20
111	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	3.4	1487
110	The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014 , 16 Suppl 2, S1	5.7	15
109	Circadian rhythms in rheumatology--a glucocorticoid perspective. <i>Arthritis Research and Therapy</i> , 2014 , 16 Suppl 2, S3	5.7	44
108	Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. <i>Clinical and Experimental Metastasis</i> , 2014 , 31, 921-33	4.7	32

107	Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1938-49	6.3	30
106	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 412	2.8	20
105	Initial immune reaction and angiogenesis in bone healing. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2014 , 8, 120-30	4.4	80
104	High-sensitivity immunofluorescence staining: a comparison of the liposome procedure and the FASER technique on mGR detection. <i>Journal of Fluorescence</i> , 2013 , 23, 509-18	2.4	8
103	Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes. <i>International Orthopaedics</i> , 2013 , 37, 145-51	3.8	69
102	Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 214-56	2.4	139
101	Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. <i>Bone</i> , 2013 , 55, 93-101	4.7	17
100	Optimized glucocorticoid therapy: teaching old drugs new tricks. <i>Molecular and Cellular Endocrinology</i> , 2013 , 380, 32-40	4.4	69
99	Human immune cells behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model. <i>Cellular and Molecular Immunology</i> , 2013 , 10, 151-8	15.4	34
98	Pathophysiological hypoxia affects the redox state and IL-2 signalling of human CD4+ T cells and concomitantly impairs survival and proliferation. <i>European Journal of Immunology</i> , 2013 , 43, 1588-97	6.1	12
97	Delayed-release prednisone - a new approach to an old therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1097-106	4	9
96	Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome. <i>Journal of Rheumatology</i> , 2013 , 40, 663-73 ^{4.1}		8
95	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 204-10	2.4	125
94	A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2013 , 52, 1435-7 ^{3.9}		15
93	Glucocorticoids 2013 , 1066-1076		
92	Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 75-9	2.4	117
91	Energy metabolism and rheumatic diseases: from cell to organism. <i>Arthritis Research and Therapy</i> , 2012 , 14, 216	5.7	27
90	Limited use of antiseptics in septic surgery. <i>Journal of Investigative Surgery</i> , 2012 , 25, 311-6	1.2	5

89	Human monocytes and macrophages differ in their mechanisms of adaptation to hypoxia. <i>Arthritis Research and Therapy</i> , 2012 , 14, R181	5.7	25
88	Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1799-808		7
87	Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases. <i>Immunologic Research</i> , 2012 , 52, 169-75	4.3	29
86	Inflammatory phase of bone healing initiates the regenerative healing cascade. <i>Cell and Tissue Research</i> , 2012 , 347, 567-73	4.2	163
85	Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2012 , 51 Suppl 4, iv14-20	3.9	10
84	The impact of Porphyromonas gingivalis lipids on apoptosis of primary human chondrocytes. <i>Connective Tissue Research</i> , 2012 , 53, 327-33	3.3	10
83	Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4172-89	15.9	128
82	Hypoxia promotes osteogenesis but suppresses adipogenesis of human mesenchymal stromal cells in a hypoxia-inducible factor-1 dependent manner. <i>PLoS ONE</i> , 2012 , 7, e46483	3.7	138
81	A fresh look at glucocorticoids how to use an old ally more effectively. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012 , 70 Suppl 1, 26-9		8
80	Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. <i>Bone</i> , 2011 , 49, 733-42	4.7	46
79	Glucocorticoids. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 891-900	5.3	51
78	Human early fracture hematoma is characterized by inflammation and hypoxia. <i>Clinical Orthopaedics and Related Research</i> , 2011 , 469, 3118-26	2.2	122
77	Exogenous and endogenous glucocorticoids in rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1-9		78
76	Origin and functional activity of the membrane-bound glucocorticoid receptor. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3779-88		48
75	How should impaired morning function in rheumatoid arthritis be treated?. <i>Scandinavian Journal of Rheumatology</i> , 2011 , 125, 28-39	1.9	12
74	Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia. <i>Journal of Immunology</i> , 2011 , 186, 764-74	5.3	44
73	Preferred use of polyhexanide in orthopedic surgery. <i>Orthopedics</i> , 2011 , 34, e664-8	1.5	9
72	Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1193, 123-6	6.5	21

71	Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 693-702	8.1	86
70	Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1275-80	2.4	79
69	Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. <i>Journal of Rheumatology</i> , 2010 , 37, 2025-31	4.1	77
68	The early fracture hematoma and its potential role in fracture healing. <i>Tissue Engineering - Part B: Reviews</i> , 2010 , 16, 427-34	7.9	238
67	More night than day--circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2010 , 37, 894-9	4.1	24
66	Pharmacology of glucocorticoids in rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2010 , 10, 302-7	5.1	31
65	Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. <i>Steroids</i> , 2010 , 75, 282-6	2.8	10
64	The association between rheumatoid arthritis and periodontal disease. <i>Arthritis Research and Therapy</i> , 2010 , 12, 218	5.7	150
63	Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. <i>Immunology Letters</i> , 2010 , 131, 24-32	4.1	11
62	The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. <i>Arthritis and Rheumatism</i> , 2010 , 62, 351-8		18
61	Inflammation, glucocorticoids and risk of cardiovascular disease. <i>Nature Clinical Practice Rheumatology</i> , 2009 , 5, 18-9		12
60	Adaptation of human CD4+ T cells to pathophysiological hypoxia: a transcriptome analysis. <i>Journal of Rheumatology</i> , 2009 , 36, 2655-69	4.1	37
59	Cellular composition of the initial fracture hematoma compared to a muscle hematoma: a study in sheep. <i>Journal of Orthopaedic Research</i> , 2009 , 27, 1147-51	3.8	60
58	Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1998-2007		43
57	The challenge of continuous exogenous glucocorticoid administration in mice. <i>Steroids</i> , 2009 , 74, 245-9	2.8	30
56	Genomic and nongenomic effects of glucocorticoids. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 525-33		343
55	Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 9, 229-240	0.3	
54	Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. <i>Steroids</i> , 2008 , 73, 1025-9	2.8	160

53	Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2008 , 371, 205-14	40	289
52	Glucocorticoids 2008 , 644-650		1
51	A case of Erdheim-Chester disease initially mistaken for Ormond's disease. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 50-5		10
50	Human CD4(+) T cells maintain specific functions even under conditions of extremely restricted ATP production. <i>European Journal of Immunology</i> , 2008 , 38, 1631-42	6.1	36
49	Arthritis and endogenous glucocorticoids: the emerging role of the 11beta-HSD enzymes. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1201-3	2.4	11
48	Glucocorticoids 2008 , 1293-1305		2
47	Glucocorticoids 2008 , 644-650		3
46	Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. <i>Molecular and Cellular Endocrinology</i> , 2007 , 275, 71-8	4.4	275
45	Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. <i>Rheumatology International</i> , 2006 , 26, 331-6	3.6	9
44	Development of cervical interspinous bursitis after prolonged sports trauma: a case report. <i>Joint Bone Spine</i> , 2006 , 73, 118-20	2.9	5
43	Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral blood mononuclear cells. <i>Biochemical Pharmacology</i> , 2006 , 71, 530-9	6	11
42	Non-genomic glucocorticoid effects to provide the basis for new drug developments. <i>Molecular and Cellular Endocrinology</i> , 2006 , 246, 142-6	4.4	155
41	Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells. <i>Transplant International</i> , 2006 , 19, 563-9		13
40	Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. <i>EMBO Reports</i> , 2006 , 7, 1023-9	6.5	112
39	Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2006 , 33, 2249-53	4.1	12
38	Optimised glucocorticoid therapy: the sharpening of an old spear. <i>Lancet, The</i> , 2005 , 365, 801-3	40	80
37	Developments in glucocorticoid therapy. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 1-17, vii	2.4	30
36	Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. <i>Blood</i> , 2005 , 106, 1703-10	2.2	126

35	Oxygen consumption and mitochondrial membrane potential indicate developmental adaptation in energy metabolism of rat cortical neurons. <i>European Journal of Neuroscience</i> , 2005 , 21, 2721-32	3.5	16
34	Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. <i>Arthritis and Rheumatism</i> , 2005 , 53, 740-7		43
33	Tumoral calcinosis revisited: pathophysiology and treatment. <i>Rheumatology International</i> , 2005 , 25, 55-93.6	29	
32	New glucocorticoids on the horizon: repress, don't activate!. <i>Journal of Rheumatology</i> , 2005 , 32, 1199-1207	29	
31	Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. <i>FASEB Journal</i> , 2004 , 18, 70-80	0.9	162
30	Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3408-17		244
29	Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1438-44		60
28	Quantitating protein synthesis, degradation, and endogenous antigen processing. <i>Immunity</i> , 2003 , 18, 343-54	32.3	415
27	Effects of norepinephrine on oxygen consumption of quiescent and activated human peripheral blood mononuclear cells. <i>Annals of the New York Academy of Sciences</i> , 2002 , 966, 365-8	6.5	6
26	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 718-22	2.4	284
25	Rapid glucocorticoid effects on immune cells. <i>Steroids</i> , 2002 , 67, 529-34	2.8	217
24	Short-term effects of the 21-aminosteroid lazaroïd tirilazad mesylate (PNU-74006F) and the pyrrolopyrimidine lazaroïd PNU-101033E on energy metabolism of human peripheral blood mononuclear cells. <i>Bioscience Reports</i> , 2001 , 21, 101-10	4.1	5
23	Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. <i>Journal of Neuroimmunology</i> , 2001 , 117, 1-8	3.5	108
22	Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases. <i>Pediatric Research</i> , 2001 , 49, 130-5	3.2	27
21	Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. <i>American Journal of Medicine</i> , 2001 , 110 Suppl 3A, 13S-9S	2.4	74
20	Signaling takes a breath--new quantitative perspectives on bioenergetics and signal transduction. <i>Immunity</i> , 2001 , 15, 497-502	32.3	110
19	Bioenergetics of immune functions: fundamental and therapeutic aspects. <i>Trends in Immunology</i> , 2000 , 21, 192-9		193
18	Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. <i>Biochemical Pharmacology</i> , 2000 , 59, 597-603	6	20

17	Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. <i>Bioscience Reports</i> , 2000 , 20, 289-302	4.1	60
16	The influence of obesity on perioperative morbidity and mortality in revision total hip arthroplasty. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2000 , 120, 267-71	3.6	59
15	Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000 , 95, 1994-9	0.7	39
14	Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. <i>Biochemical Pharmacology</i> , 1999 , 58, 363-8	6	114
13	Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1999 , 1412, 129-38	4.6	32
12	A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. <i>Arthritis and Rheumatism</i> , 1998 , 41, 761-7		178
11	Clinical image: Isolated arteritis of the superior mesenteric artery with positive perinuclear antineutrophil cytoplasmic antibody. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1701		3
10	Methylprednisolone inhibits uptake of Ca ²⁺ and Na ⁺ ions into concanavalin A-stimulated thymocytes. <i>Biochemical Journal</i> , 1997 , 326 (Pt 2), 329-32	3.8	45
9	Reply: To the editor. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1185-1186		
8	Reply: Finger exostosis caused by drumming? Comment on the clinical image report by Buttgereit and Burmester. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1185-1186		
7	Clinical images: Drummer's finger. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1258-1258		1
6	The influence of methylprednisolone on the energy metabolism of Ehrlich ascites tumour cells. <i>Bioscience Reports</i> , 1994 , 14, 283-90	4.1	3
5	The effects of methylprednisolone on oxidative phosphorylation in Concanavalin-A-stimulated thymocytes. Top-down elasticity analysis and control analysis. <i>FEBS Journal</i> , 1994 , 223, 513-9		43
4	Effects of methylprednisolone on the energy metabolism of quiescent and ConA-stimulated thymocytes of the rat. <i>Bioscience Reports</i> , 1993 , 13, 41-52	4.1	26
3	Quantification of ATP-producing and consuming processes of Ehrlich ascites tumour cells. <i>FEBS Journal</i> , 1986 , 161, 701-5		56
2	HIF-stabilization prevents delayed fracture healing		1
1	A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited		2